Investigating The Role of Radiomics in Predicting Treatment Response and Patient Outcomes in Oncology

[1]Aqsa Mansoor Dar, [2]Maida Zulfiqar , [3]Dr Kinza Shafiq, [4] Marwa Ali , [5]Qurait Maqsood, [6]Mobeen Ali [7]Kashif Lodhi

[1]Frontier Medical College Abbotabad [2]Fatima Jinnah University, Lahore
[3]Fatima Jinnah medical college Lahore
[4]PIMS
[5]Poonch Medical College Rawalakot
[6]PIMS
[7]Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecc

Abstract

Background: Radiomics, as the process of acquiring and analysing quantitative imaging characteristics, is the novel method which has been actively investigated in oncology for its ability to estimate treatment response and patients' survival based on the CT, MRI and PET imaging.
Aim: Therefore, the aim of this study is to understand the use and significance of radiomics in forecasting treatment responses and the course of oncological diseases in the context of modern oncology's weaknesses in cancer individualization, as well as the importance of proper prediction.
Method: A specific strategy was utilizing a retrospective cohort study, that involved the assessment of radiomic features based on medical images and patients' information from their records. It was used statistical and machine learning approaches to extract and use radiomic features, and to build prediction models. In this study ethical considerations were considered.

Results: Participants' demographic data, cancer diagnosis, and extent were considered. The important aspects for explaining the treatment responder population were delineated, and performances for several statistical models were confirmed and compared across different cohorts. Survivals and recurrences where other patients did or did not experience were considered, along with major subgroups to identify that the predictions' accuracy regarding the occurrence of cancer were based on the type, stage, and treatment plan.

Conclusion: In oncology, the application of radiomics becomes evident and important as it defines the role to predict the response of the treatment as well as patient prognosis. Its integration can be expected to help in progressing cancer treatment methods and the best practices for patients' management and therefore meaningfully impact the field of oncology.
Keywords: Radiomics, Oncology, Treatment Response, Patient Outcomes, Predictive Modelling, Medical Imaging, Machine Learning, Personalized Medicine.

Introduction

The use of imaging in association to computational data analysis is defined as radiomics, a breakthrough technology that has been discovered in the oncology environment. As mentioned before, the term radiomics is used to describe the extraction and analysis of large numbers of advanced quantitative imaging features with the aim of developing big data diagnostic and prognostic models. Originally designed to improve the functions of medical imaging, the approach of radiomics analyses the information that can be obtained even from the pictures that people cannot discern. Clinically speaking, this has significantly altered the way imaging results are being interpreted by the clinicians from purely qualitative to qualitative and quantitative measures. The origin of radiomics is dependent with the development of imaging techniques and computational capabilities. Originally, only comparatively simple features of the image of the tumour were considered, now the area has developed greatly due to high-throughput computation. Radiomics now includes intensity shape, texture as well as wavelet transforms which is a rich repository on tumour biology. They have far-reaching consequences for oncology, and its critical components, including accurate and early diagnosis, and efficient treatment planning [1]. One of the major concerns in the field of oncology is identification of biomarkers that would help in estimating the response to the treatment or prognosis of the patients. Even though, cancer treatment has substantially taken a new turn, it is still challenging to determine how a patient will fare with a specific therapy.

The current practices which focus on examinations on clinical and pathological basis are inadequate in describing the nature of the tumors as their variation is immense. Thus, there arises a high demand for more accurate and client-specific risk assessment models.This is where radiomics comes up helpful. In other words, while conventional radiological analysis delivers quantitative estimations at the organ and tissue levels, radiomics elaborates exhaustive descriptors of the tumor microstructure and can potentially uncover workable imaging biomarkers to predict the therapeutic outcome and the patient survival. There are several prospects for potential benefits in the precise prediction of response to treatment and patients' prognosis. On the patients' side, it can result in the better treatment planning and individual approach as well as the ability of avoidance of side effects that are connected with typical tumors. Thus, for clinicians, the proposed radiomics-based predictive models can be helpful in reaching more effective decisions on treatment plans. In addition, it will be possible to make more rational distribution of health care resources, thus excluding the losses derived from the inefficiency of treatments [2]. Radiomics is conducted through a multistep process and Subsequent to image acquisition. For example, the detailed tumor characteristics require the intake of quality imaging capabilities like CT, MRI, or a PET scan. The next stage includes segmentation, in which the area of interest, usually the tumor, is usually outlined. This is succeeded by feature extraction that involve the computation of hundreds if not thousand of quantitative features from the segmented images. Such features may comprise the absolute and relative levels of the tumor, the tumor's symmetry or irregularity, or even some higher-order statistical characteristics. The next step involves using complex statistical and machine learning techniques to extract the features, pattern and generate predictive models. Speaking of the case with cancer and its diagnosis and treatment, radiomics has the following benefits. In diagnosis, the feature extracted from radiomics can be used to distinguish between benign and malignant, types of cancer and genetic mutations of the tumor. In the context of treatment or, at least, during the development of a treatment plan, the radiomic enables the determination of prognosis, which can affect the choice of the therapy type [3]. For example, there could be some predefined radiomic features that associated with higher probability of chemosensitivity or radiosensitivity. In the follow-up phase, radiomics is valuable for evaluation of response to the treatment as for early signs of relapse [4].

That is why the aim of this research is to explore the value of radiomics in the context of treatment response prediction and patients' prognosis in oncology. This includes a systematic review of the most recent literature and review of clinical implementation of radiomics with the view of assessing the accuracy of the models that exist in practice. In this study, the authors want to investigate which radiomic features are most prognostic regarding the treatment and what the methodologies of feature extraction as well as model construction of existing studies are, and finally, what the performance of radiomics in clinical practice is. Furthermore, this study proposes to investigate the modality by which radiomic features predict treatment response and overall survival. This is carried out by investigating the biological importance of specific radiomic features and how they manifest with tumour biology features such as cell density, vasculature, and hypoxia. Knowledge of these mechanisms can explain why some tumors are inconsistent with treatments and how to convey the discrepancy to improve radiomic models [5].

Lastly, this research aims at shedding light on how radiomics can revolutionise oncology. In this respect, the present work is designed to enhance the understanding of how the concept of precision medicine can be applied to cancer treatment based on a comprehensive assessment of its outcomes' applicability, advantages, and drawbacks. Consequently, it aims at creating a foundation for one to carry out additional research for which can handle current problems and improve the implementation of radiomics in clinical practice settings. Thus, with time, one can expect the application of radiomics to enhance cancer- associated therapy and advance oncology as a field [6].

Methodology

The methodology of the current study, which aimed at exploring the value of radiomics for the prediction of treatment outcomes and the patients' overall prognosis in oncology, implies a structured approach and a retrospective cohort study. Surprisingly, this design is suitable for this type of research, as radiomic features and their patterns can be studied based on existing data, whereas in the previous approaches, a full picture of errors was analysed, illustrating how radiomic features correspond to the clinical outcomes. The strengths of retrospective studies include their ability to review a large volume of patient data as well as numerous imaging cases to obtain conclusions about phenomena that may be difficult to identify in studies that are conducted in the future. The data sources for this study are twofold: imaging diagnosis and patients' charts [7]. Critical to radiomics is medical imaging data as radiomics uses image data to extract quantitative features. These categories of imaging data include, computed tomography scans, magnetic resonance imaging, positron emission tomography scans. Each of the modalities has its benefits: for example, while CT gives high- resolution morphological information, MRI provides a better delineation of soft tissues, and PET indicates tissue's metabolism. The three imaging techniques as a whole offer a wealth of information input that can be used in radiomic analysis [8].

Besides imaging data, patient records are essential to this study. These records include data on patient's age, sex, diagnosis, therapeutic plan, and response to the treatment. Integration of the imaging data with the records ensures that other clinical data is included, which helps in evaluating the relationship between the radiomic features and the treatment outcomes. These include the overall survival, PFS and response to certain treatments among others; details of which are recorded in the patients' charts, making them usable for research [9]. Champion and Pillow (2008) have pointed out that the criteria used to select the participants are the most important factor that determines the credibility of the entire research. Common characteristics for selecting patients are cancer types; patients must have the same imaging techniques used; sufficient medical records should be available. Such criteria are important to make sure that the collected data is similar and can be compared from one patient to another. For instance, exclusion criteria could be patients with missing data, patients who have been treated with other treatments than the ones that are standard in the study, or cases with poor quality images for radiomic analysis. Again, this choice ensures that the researchers do not fall into the pitfalls of systematic and random errors during the study [10], Imaging and clinical data constitute the data collection methods. In the case of imaging data, radiomic features extraction is a process that requires the following steps. First, boundaries of the region of interest (ROI), generally, the tumor is defined by using the semi-automated or manual techniques. This segmentation process is vital as it established the region from where radiomic attributes will be derived. After that, more complex computational algorithms are used with a view of extracting numerous features from the segmented images. We can divide them into several classes such as intensity base feature, shape descriptor, Texture feature and the higher-order statistical features [11]. All of these categories give different information on the nature of the tumor, its size, shape, texture and the heterogeneity of the tumor's spatial distribution in relation to the surrounding healthy tissue. However, as the need for assessment of clinical data increases, the problem of the need for a full collection of information about patients arises. This is the core of information that defines patient's background (age, gender, comorbidities), cancer type (stage, histological type), and treatment history, including chemotherapy, radiation therapy, and surgery. The most important thing is how the treatment is effective, and the results are tracked down to the smallest detail. The response to treatment could be assessed by using items like the Response Evaluation Criteria in Solid Tumors (RECIST), while the results are dominated by indicators such as overall survival and progression-free survival [12].

The general steps of data analysis include statistical and machine learning aspects. First of all, the basic characteristics of radiomic features and clinical profiles of the study sample are tabulated using mean, median, standard deviation, and frequencies. This step offers slight information on the data collected so that the researchers are in a position to notice any extreme values [13]. The next step is the more complex statistical tests to identify correlations between the radiomic features and outcomes. Subgroup analysis, including the use of survival analysis (for example, Kaplan- Meier curves and the Cox proportional hazards models are employed to evaluate the prognostic worth of radiomic characteristics. Supervised models are hugely useful in identifying the likelihood of a patient to respond to the treatment and subsequent prognosis. There exist methods such as support vector machine, random forest, and neural network to construct a predictive model. Such models are learned on a part of the data set and tested on the independent one to check the models' applicability. The effectiveness of these models is then assessed in terms of such indices as accuracy, sensitivity, specificity, and the area under the curve of receiver operating characteristic (AUC ROC). Popular techniques applied for achieving the feature selection include, for instance, the recursive feature elimination or the LASSO regression, helping to transform the set of radiomic features into the most informative set, which would improve the model interpretability and predictive capabilities [14]. Thus, adhering to the highest standards of ethical consideration is especially imperative to this study. The patient's confidentiality is an essential aspect during the treatment, especially when dealing with medical records and images. To overcome these difficulties, the patient's identity is masked through data anonymization techniques and the data stored in secure databases. Also, the study must meet the requirement of getting approval from an institutional review board (IRBs) or an ethics committee. Such approvals guarantee that the planned study meets ethical benchmark and that of patient's right and well-being every time [15].

Results

The findings of our published systematic review focusing on the application of radiomics to assess the response to treatments and patients' prognosis in oncology are reusable and valuable in many aspects. The participant characteristics were collected at the start of the analysis to provide basic information regarding their age, gender, cancer type and stage. This fundamental data is very important as it helps to control and check the representativeness of the given cohort and gives more possibilities to interpret radiomic characteristics and their predictive potential in details. The population represented the target spectrum of patients from early middle age to the late years, which accurately characterizes the problem of cancer in modern society. While both male and females were equally involved, the utilization of samples did differ according to the different types of cancer identified. The analysed types of cancer comprise a broad spectrum, from the most frequently diagnosed ones, such as breast, lung, and colorectal cancer, to the rarer patients with pancreatic and ovarian cancer. For each cancer type, distinct stages of cancer, beginning from the early stage to advanced were considered so as to perform a complete assessment of the association between radiomic features and treatment response and outcomes by cancer stage [16].

Among the essential discoveries of the study, we were able to establish the existence of features of radiomics that are closely related to response to treatment. These HRFs that were derived from imaging such as CT, MRI and PET scans were giving tons of information. Among the features, the texture parameters like entropy and homogeneity were found to have very high performance. Concerning the intensity of the tumour images, they noted higher entropy, which describes the randomness of pixel intensity in the tumours of the male patients whose tumour was more heterogeneous and disordered. However, homogeneity, which characterized by the level of the pixel's intensity, was generally smaller in such tumors. The texture features combined with the shape and intensity descriptors were found to be significantly correlated with the treatment outcomes. For example, higher entropy of primary tumors indicated poor response to conventional therapies and thus radiomic markers could be useful in tasks such as treatment planning. To elaborate the relationship between those radiomic features and treatment responses, complex statistical methods were applied. In addition, using correlation measures and regression Analysis, it was possible to assess the extent and direction of the association between distinct radiomic features and clinical results. For instance, lower pre-treatment entropy was always linked to better chemosensitivity and the ability to work with different or more intensively aggressive treatment regimens [17].

To enable the use of these findings for designing practical tools for outcome prediction based on radiomic features, we constructed and internally validated several machine learning models focused on treatment response prediction. Some of these models consisted of recommended algorithms, which included support vector machines, random forests and the neural networks. The efficiency of these models was highly assessed based on the parameters such as accuracy, sensitivity, specificity, and AUC- ROC. The performance was quite good, and some models of classifiers showed high accuracy and margin of error in the prediction of treatment outcomes. For example, the random forest model reported the AUC-ROC of 0. 85 in the validation cohort suggesting good calibrations, thereby manifesting good predictive ability. To our knowledge, this is the first study to report on such models in identifying phenotypical associations of depression, and these models were cross validated across the two datasets. This included, partitioning of data into training and validation sets as well as external testing on datasets from different institution. The models' good performance on these datasets highlighted their practical applicability in various clinical contexts and therefore opened up a wide range of usage in the field of oncology [18].

The current work's analysis of patient outcomes also highlighted the correlation between radiomic features and overall survival and recurrence. Patients with more heterogeneous and of higher entropy tumors generally had a lower overall survival, and higher recurrence rates. Based on these results, the present study indicates that radiomic features could potentially be used for prognosis as biomarkers to determine patients' risk levels and make relevant treatment suggestions. A separate analysis of the results provided by the subgroups provided more insight into the ability of radiomic features to predict the outcome. Thus, their analysis using patients' classification by cancer type, stage and the type of treatment showed important distinctions. For instance, the discriminative ability of radiomic based models was slightly different across the cancer types; some features were more discriminating of specific cancers. Hence, for breast cancer, the texture features were more and more informative regarding the response to

Key Findings	**Radiomic Features**	**Clinical Applications**
Radiomic features significantly correlate with treatment response.	Texture parameters (entropy, homogeneity), shape descriptors, intensity characteristics.	Useful in treatment planning and predicting response to therapies based on tumor heterogeneity and complexity.
Lower pre-treatment entropy associated with better chemosensitivity.	Entropy as a predictor of treatment outcomes; higher entropy linked to poorer response to conventional therapies.	Provides insights into choosing appropriate treatment regimens based on radiomic markers.
Machine learning models (e.g., SVM, random forests, neural networks) developed.	Models evaluated for accuracy, sensitivity, specificity, and AUC-ROC.	High predictive ability (e.g., AUC-ROC of 0.85 for random forest) in treatment response prediction, applicable across different datasets.
Radiomic features correlate with overall survival and recurrence rates.	Heterogeneous tumors (higher entropy) linked to lower overall survival and higher recurrence rates.	Potential use as biomarkers for prognosis, aiding in risk stratification and treatment recommendations.

the hormone treatment while for the lung cancer, the shape descriptors remained most informative in terms of the response to radio treatment. In the same way, when it came to radiomic features, the stage of cancer affected the predictive outcomes; these included differences in feature profiles derived from early-stage tumors and tumors at an advanced stage. Also, when it comes to the type of treatment that was given the radiomic models' predictive efficacy was influenced. Using these parameters, certain different intensity-based features were more significant for the patient's receiving chemotherapy, while the texture and the shape features were more beneficial in making forecasting for the patients receiving targeted treatments. These studies serve to emphasize that the models trained should incorporate features that are aligned with the specifics of clinical applications of radiomics.

Variability in feature importance across cancer types and stages.	Texture features more informative for breast cancer (e.g., hormone treatment response); shape descriptors crucial for lung cancer (e.g., radiotherapy response).	Tailoring radiomic models based on cancer type, stage, and treatment type enhances predictive accuracy and clinical relevance.

Discussion

The review section of the present study on application of radiomics for identifying treatment response and patient survival in oncology is focused to compare our findings with prior studies, discussion of the possible reason for our result, application point of view for method in clinical and health field, and study and research limit of present work. Our results are aligned to the existing literature suggesting significant reliability of radiomics as a prognostic measure in oncological patients. These studies have proven the ability of radiomic features in predicting several clinical endpoints, response to therapy and survival rates. These results conform to the outcomes of these studies more specifically, in which we find some of the intrinsic radiomics features whose importance has been highlighted previously, specifically entropy and homogeneity. Yet, our study has contributions not given by previous ones, where we included different cancer types and more stages of the disease, which allows for a broader view of the flexibility and uses of radiomics in different contexts. Also, the employment of various machine learning techniques presents a more contemporary method of affirming the prognosis ability of these features towards future applications in the oncology field. The implications for the outcomes of the study that we discovered encompass both the biological and the technical prospective. From a biological standpoint, the described radiomic features pertain to the tumor biology as well as its architectural pattern, which are critical in determining disease growth and the effectiveness of therapy. The term entropy characterizes disorder and heterogeneity and is implicated with malignancy and treatment resistance. Texture on the other side is characterized inasmuch as high homogeneity values corresponds to simple and easy to treat tumors as opposed to high complexity tumors with low homogeneity values. These biological substrates correspond well with the associations between the radiomic features and clinical data evidenced. From a technical point of view, tumor images acquired by contemporary imaging techniques like CT, MRI or PET can be characterized with high resolution and accurate positioning, allowing depiction of very high number of radiomic descriptors reflecting incremental differences in the tumors' morphology and texture. This technical capability reinforces the application of radiomics as a diametrical method of acquiring precise prognostic details from the patients [19].Radiomic predictions, accuracy of the theoretical models aimed at understanding, integrates biological characteristics with machine learning. Radiomic features include the geometry of the tumor and variations of the tissue density within it to help quantify the behaviour of the lesion. The quantitative features are then used to train machine learning models that use their inherent ability to identify patterns and map them to high levels of clinical outcomes. This integration of radiomics and machine learning signifies that the cancer treatment process does not have to be vanilla- like but can depend on the unique characteristics of the tumor present in the patient. The application to the clinical practice therefore has major implications as it points to the fact that radiomic features may be incorporated into the clinical decision process to support care delivery. Since radiomics delivers detailed and minimally invasive information about the tumor characteristics, it will be of immense help to the oncologists in the choice of the therapy type, as well as its modification. This concept fallows the idea of Ge nomic Medicine where treatment schedules are formulated depending on the profile of the tumor of the particular patient. For example, high entropy in the tumor sample might mean the patient is referred to more aggressive or other treatment methods from the start of cancer treatment, resulting in better results and diminished negative side effects.

Non-clinical effects bear larger impacts influencing the management of cancer and allocation of available resources that goes beyond the client's own benefit. It is postulated that the integration of radiomics across various diagnostic and prognostic techniques may increase the specificity of high-risk patients' identification at an earlier stage. This preventive strategy can enhance the outcomes of the applied treatment and may reduce the expenses needed to provide adequate care due to the prevention of the application of ineffective therapies. Also, the application of radiomics in the clinic may improve the availability of accurate diagnostic techniques and may, therefore, have profound implications to patients in underprivileged areas where biopsy methods may not be easily applicable. For implementation, the proposals include: the elaboration of standardized radiomic procedure and bilateral cooperation between radiologists, oncologists, and data scientists to incorporate radiomic techniques into ongoing workflows

[20]. Nevertheless, the present study is also not without some limitations that should be noted down for consideration: Several limitations are characteristic of the used methodological approach On the methodological level, the chief advantage but also disadvantage of the retrospective design used here is that the access to large amounts of already collected data may not be biased and the study may profit from the comparative character, still, it can be rather selective in patient sampling and in the completeness of the data to be used. Future research should propose prospective designs to assess whether the radiomic features have good predictive abilities in actual clinical environments. Thirdly, although the sample incorporated a sufficient number of participants, its generalization to further populations or subtypes of cancer may remain restricted. Another issue associating with geometrical data is relating to the imaging and quality data since the different protocols of the imaging methods and the types of scanners lead to differences in the geometry in extraction of the radiomic features. Such limitations can be addressed to, by enhancing the process of standardisation hence increasing the reliability of the results acquired using radiomic analysis. The present work also highlights the above limitations and recommends the future works in order to develop the range of radiomic research. Further prospective investigations using bigger and comparatively diverse populations of patients are needed to support the application of radiomics for the estimation of liability to treatment response and survival. Further, expanding the range of radiomic features, which could be extracted from new imaging

techniques, it could be possible to find new indicators which could give more accurate and complete evaluation of the radiomic characteristics. The newer approaches of machine learning and deep learning support the possibility of designing new models with higher heterogeneity, including the possibility of modelling the features of radiomic data in more detail. These models should be tested and validated in other independent data sets so that their predictive power can be ascertained.

Conclusion

The systematic review concerning the impact of radiomics in evaluating the treatment response and patients' prognosis in oncology have established that radiomics has that great a potential that would redefine cancer treatment. In other words, radiomics refers to the use of CT, MRI, and PET scans, and other imaging techniques to identify detailed characteristics of tumors and surrounding tissues, which can later be used to predict patients' reactions to treatments and life expectancy. This approach is relevant to today's issues in oncology by generating better and more specific predictions, which are essential for assessing the optimization of treatment plans for each subject. Due to the retrospective cohort design of the study, using a large amount of medical imaging and patient files, the most important radiomic characteristics relevant to the treatment outcomes have been described and there is evidence of the applicability of machine learning models for making these predictions. The same is repeated when validating these models on other datasets to ensure their generalisability. Of course, the methodological limitations include a small sample size and data quality, however, the results are still consistent with the literature and complement it with the biological and technical explanation of successful radiomic features. In clinical expertise, the applicability of radiomics in routine procedure is perhaps the most beneficial

to change the course of unfavourable patient prognosis and perhaps make optimum utilization of resources in the process. At the population level, this might result in better overall organization of the treatment of cancer patients and increased availability of sophisticated diagnostic equipment. It is crucial to highlight the value of the study due to its prospective design, which can be regarded as its strength and future opportunities for furthering the utilization of novel radiomic features as well as the improvement of machine learning algorithms. Finally, this work enriches the knowledge of oncology as a discipline, including the correlation between radiomics and the further promotion of its use in clinical practice for the better management of cancer patients.

References

[1] S. Trebeschi, "Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers," *Annals of Oncology,* vol. 30, no. 6, pp. 998-1004, 2019.

[2] F. C. Staal, "Radiomics for the Prediction of Treatment Outcome and Survival in Patients With Colorectal Cancer: A Systematic Review," *Clinical Colorectal Cancer,* vol. 20, no. 1, pp. 52-71, 2021.

[3] T. P. Coroller, "Radiomic phenotype features predict pathological response in non-small cell lung cancer," *Radiotherapy and Oncology,* vol. 119, no. 3, pp. 480-486, 2016.

[4] G. Walls, "Radiomics for Predicting Lung Cancer Outcomes Following Radiotherapy: A Systematic Review," *Clinical Oncology,* vol. 34, no. 3, pp. e107-e122, 2022.

[5] T. P. C. MSc, "Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC," *Journal of Thoracic Oncology,* vol. 12, no. 3, pp. 467-476, 2017.

[6] H. Li, "Unsupervised machine learning of radiomic features for predicting treatment response and overall survival of early stage non-small cell lung cancer patients treated with stereotactic body radiation therapy," *Radiotherapy and Oncology,* vol. 129, no. 2, pp. 218-226, 2018.

[7] V. Salvestrini, "The role of feature-based radiomics for predicting response and radiation injury after stereotactic radiation therapy for brain metastases: A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO)," *Translational Oncology,* vol. 15, no. 1, p. 101275, 2022.

[8] R. Granzier, "Exploring breast cancer response prediction to neoadjuvant systemic therapy using MRI-based radiomics: A systematic review," *European Journal of Radiology,* vol. 129, p. 108736, 2019.

[9] G. Wang, "Pretreatment MR imaging radiomics signatures for response prediction to induction chemotherapy in patients with nasopharyngeal carcinoma," *European Journal of Radiology,* vol. 98, pp. 100-106, 2018.

[10] M. Fan, "Radiomic analysis of DCE-MRI for prediction of response to neoadjuvant chemotherapy in breast cancer patients," *European Journal of Radiology,* vol. 94, pp. 140-147, 2017.

[11] I. Tunali, "Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report," *Lung Cancer,* vol. 129, pp. 75-79, 2019.

[12] C. Lian, "Selecting radiomic features from FDG-PET images for cancer treatment outcome prediction," *Chunfeng Lian,* vol. 32, pp. 257-268, 2016.

[13] R. Forghani, "Radiomics and Artificial Intelligence for Biomarker and Prediction Model Development in Oncology," *Computational and Structural Biotechnology Journal,* vol. 17, pp. 995-1008, 2019.

[14] Y. M. Park, "Prediction of treatment outcome using MRI radiomics and machine learning in oropharyngeal cancer patients after surgical treatment," *Oral Oncology,* vol. 122, p. 105559, 2021.

[15] P. Bulens, "Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics," *Radiotherapy and Oncology,* vol. 142, pp. 246-252, 2020.

[16] J. E. v. Timmeren, "Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images," *Radiotherapy and Oncology,* vol. 123, no. 3, pp. 363-369, 2017.

[17] G. Lee, "Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art," *European Journal of Radiology,* vol. 86, pp. 297-307, 2017.

[18] C. Zhang, "Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes," *Methods,* vol. 188, pp. 61-72, 2021.

[19] D. Ou, "Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status," *Oral Oncology,* vol. 71, pp. 150-155, 2017.

[20] P. Wen Yu MD, "Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer," *International Journal of Radiation Oncology*Biology*Physics,* vol. 102, no. 4, pp. 1090-1097, 2018.